The article discusses the approval of Bayer Eylea 8 mg in the European Union for the treatment of two major retinal diseases. This medication is used to treat neovascular (wet) age-related macular degeneration and visual impairment due to diabetic macular edema. The approval allows for the use of a higher dose of Eylea, providing potential benefits for patients suffering from these conditions. The article also mentions the use of cookies for analytics and advertising on the website, with a link to the site’s Cookie Policy and Cookie Settings for more information.
Source link
Bayer Eylea 8 mg approved in EU for treatment of two major retinal diseases
